Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 6/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | SOS1 | Q07889 | 4/20 | 0.50 |
| ▸ | CDK1 | P06493 | 3/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.49 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.48 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 5/20 | 0.47 |
| ▸ | CA1 | P00915 | 4/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 4/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA4 | P22748 | 2/20 | 0.46 |
| ▸ | CA7 | P43166 | 2/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.45 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4466766 | 0.88 | CDK2 (0.62) | CDK2SOS1CDK1CA2CA1 | |
| SCHEMBL5510994 | 0.87 | CA12 (0.50) | CDK2MEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL13931766 | 0.87 | CDK2 (0.48) | CDK2MEN1MAPTMAPK1KMT2A | |
| SCHEMBL4476707 | 0.87 | CDK2 (0.62) | CDK2SOS1CDK1PTGS2CA2 | |
| SCHEMBL13918111 | 0.87 | IKBKB (0.54) | CDK2MEN1MAPTKMT2ACDK1 | |
| Gw831091X SCHEMBL4464647 | 0.85 | CDK2 (0.65) | CDK2MEN1MAPTMAPK1KMT2A | |
| SCHEMBL13931858 | 0.85 | CDK2 (0.46) | CDK2MEN1MAPTMAPK1KMT2A | |
| SCHEMBL4460780 | 0.84 | CDK2 (0.65) | CDK2MEN1MAPTMAPK1KMT2A | |
| SCHEMBL4466135 | 0.82 | CDK2 (0.68) | CDK2MEN1MAPTMAPK1KMT2A | |
| SCHEMBL4467252 | 0.80 | CDK2 (0.64) | CDK2MEN1MAPTMAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7507834-B2 | Substituted anilinopyrazoles | SMITHKLINE BEECHAN CORPORATION (US) | 2009-03-24 | — | — | US | claimed |
| EP-1597234-B1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2008-10-08 | — | — | EP | claimed |
| EP-1597234-A4 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2007-11-21 | — | — | EP | claimed |
| US-20060142284-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION | 2006-06-29 | — | — | US | claimed |
| EP-1597234-A2 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-11-23 | — | — | EP | claimed |
| WO-2004076414-A2 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-09-10 | — | — | WO | claimed |
| US-7507834-B2 | Substituted anilinopyrazoles | SMITHKLINE BEECHAN CORPORATION (US) | 2009-03-24 | — | — | US | disclosed |
| US-7507834-B2 | Substituted anilinopyrazoles | SMITHKLINE BEECHAN CORPORATION (US) | 2009-03-24 | — | — | US | disclosed |
| US-7507834-B2 | Substituted anilinopyrazoles | SMITHKLINE BEECHAN CORPORATION (US) | 2009-03-24 | — | — | US | disclosed |
| EP-1597234-B1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2008-10-08 | — | — | EP | disclosed |
| EP-1597234-A4 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2007-11-21 | — | — | EP | disclosed |
| US-20060142284-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION | 2006-06-29 | — | — | US | disclosed |
| EP-1597234-A2 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004076414-A2 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142284-A1 | Novel compounds | CDK2, CDK3, CDK2AP2 | CDK2 1/4885MEN1 2277/4885MAPT 3157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.